ArticlePloS one2019
The characteristics and treatment patterns of patients with Parkinson's disease in the United States and United Kingdom: A retrospective cohort study.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Case Definitions and Data Sources for NNCSS Parkinson Disease Surveillance: A Systematic Review.JAMA network open · 2026Pooled it
- Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta-Analysis.European journal of neurology · 2026Pooled it
- Devices for remote continuous monitoring of people with Parkinson's disease: a systematic review and cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2024Pooled it
- Pooled it
- Reproducible Generalized Thermal Sensation Triggered by Levodopa in a Patient With Parkinson's Disease.Journal of medical cases · 2026Article
- Comparative Analysis of the Incidence, Prevalence, and Survival of 8 Types of Parkinsonism in a Population-Based Study with 367 Million Person Years of Observation over 21 Years.Movement disorders clinical practice · 2026Observational
- A soft magnetoelastic ball for self-powered Parkinson's disease diagnosis.Cell biomaterials · 2026Article
- Article
- The Effects of Repetitive Transcranial Magnetic Stimulation on Gait, Motor Function, and Balance in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2025Review
- Longitudinal Study of Treatment Variability for Parkinson's Disease across Specialized Centers.Movement disorders clinical practice · 2025Article
- Understanding the experience of prescription charges in people living with parkinson's disease: a focus group study.BMC public health · 2025Article
- Fears and uncertainties of people with Parkinson's disease.Journal of Parkinson's disease · 2025Article
- Diagnosing Parkinson's disease via behavioral biometrics of keystroke dynamics.Science advances · 2025Article
- Drug utilization study of antiparkinsonian medication in Romania during 25 years.Frontiers in pharmacology · 2025Article
- Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024).PloS one · 2025Article
- Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST.PloS one · 2024Observational
- Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Dopaminergic treatment strategies for people with Parkinson's disease in Europe: a retrospective analysis of PRISM trial data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson's Disease.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Time until modification of antiparkinsonian therapy in a group of patients from Colombia.Revista de neurologia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of the study was to describe treatment patterns in patients newly diagnosed with Parkinson's disease (PD) in the United States (US) and the United Kingdom (UK).
methodsThis retrospective cohort study used the US IBM MarketScan database (2012-2017) and the UK Clinical Practice Research Datalink (CPRD) (2004-2015) database to describe treatment patterns in incident PD cases. Patients fulfilling the case definition of PD, ≥30 years, with a 2-year baseline period prior to the index date (date of PD diagnosis), and ≥90 days of follow-up were included in the study. Treatment was classified as monotherapy (one PD medication for ≥60 continuous days), polytherapy (at least two PD medications concurrently for ≥60 days), or untreated (no PD medication prescription). Treatment patterns described included type of medication, duration and outcome of treatment.
resultsThere were 11,280 patients in IBM MarketScan and 7775 patients in CPRD who fulfilled the study criteria. The proportion of treated patients was 62.4% (US) and 78.6% (UK). The majority of patients were prescribed monotherapy as first-line treatment (US: 85.2%, UK: 68.5%). Levodopa was the most frequently prescribed first-line medication (US: 70.1%, UK: 29.0%). There were 57.9% in the US and 23.8% in the UK who remained on the first monotherapy treatment till the end of the study.
conclusionThe study has highlighted the current treatment practices in the US and UK, and underscored differences in the two regions impacted by treatment policies and guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.